Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial

202410 citationsJournal Articlegold Open Access

Authors

Mepolizumab provided clinical benefits to patients with severe asthma in China and showed a favourable benefit-risk profile.

Good health and well-being

Published in: ERJ Open Research

Volume 10, Issue 3, pp. 00750-2023

Field-Weighted Citation Impact: 3.30